Fracture Incidence, Quality of Life, and Back Pain during 18-Months Treatment with Teriparatide in Greek Postmenopausal Women with Osteoporosis: Results from the European Forsteo Observational Study
Objective. To evaluate fracture incidence, effects on health-related quality of life(QoL), back pain (BP) occurrence and treatment compliance in Greek post-menopausal osteoporotic women treated with teriparatide (TPTD) for up to 18 months, in a naturalistic setting. Methods. 301 patients provided ba...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Journal of Osteoporosis |
| Online Access: | http://dx.doi.org/10.4061/2011/510398 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552251649949696 |
|---|---|
| author | K. Aloumanis D. Karras V. Drossinos E. Korelis A. Polydorakis |
| author_facet | K. Aloumanis D. Karras V. Drossinos E. Korelis A. Polydorakis |
| author_sort | K. Aloumanis |
| collection | DOAJ |
| description | Objective. To evaluate fracture incidence, effects on health-related quality of life(QoL), back pain (BP) occurrence and treatment compliance in Greek post-menopausal osteoporotic women treated with teriparatide (TPTD) for up to 18 months, in a naturalistic setting. Methods. 301 patients provided baseline information on demographic characteristics, fracture history, osteoporosis-related medication and risk factors. During treatment, QoL and BP severity were evaluated. Results. Mean (SD) age was 69.5 (±8.5) years. Fracture history was reported by 92.5% of patients. Incidence of fractures (per 10,000 patients/years) ranged from 402 during 0–6 months of treatment, to 346 during 12–18 months. All 5 dimensions of QoL showed improvement. At baseline and 18 months, BP was reported by 93.2% and 64.2% of patients, respectively. BP and limitation of activities were quantified as moderate or severe by 89.9% and 62.3% of patients at baseline versus 32.4% and 14.8% at 18 months. Patients on treatment at 6, 12, 17, and 18 months were 92.6%, 88.3%, 79.6%, and 36.5%, respectively. Conclusions. In the Greek EFOS study cohort, patients prescribed TPTD were severely osteoporotic, with considerable health-related problems. Significant improvements in QoL and BP together with low fracture rates and high compliance have been recorded during treatment. |
| format | Article |
| id | doaj-art-bde64836e2a74a8c9a35eee1958dde30 |
| institution | Kabale University |
| issn | 2042-0064 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Osteoporosis |
| spelling | doaj-art-bde64836e2a74a8c9a35eee1958dde302025-02-03T05:59:18ZengWileyJournal of Osteoporosis2042-00642011-01-01201110.4061/2011/510398510398Fracture Incidence, Quality of Life, and Back Pain during 18-Months Treatment with Teriparatide in Greek Postmenopausal Women with Osteoporosis: Results from the European Forsteo Observational StudyK. Aloumanis0D. Karras1V. Drossinos2E. Korelis3A. Polydorakis4Department of Medical Research, Pharmaserve-Lilly, Kifissia, 14564 Athens, GreeceRheumatology Department, Veterans Administration Hospital, 11521 Athens, GreeceDepartment of Medical Research, Pharmaserve-Lilly, Kifissia, 14564 Athens, GreeceDepartment of Medical Research, Pharmaserve-Lilly, Kifissia, 14564 Athens, GreeceDepartment of Medical Research, Pharmaserve-Lilly, Kifissia, 14564 Athens, GreeceObjective. To evaluate fracture incidence, effects on health-related quality of life(QoL), back pain (BP) occurrence and treatment compliance in Greek post-menopausal osteoporotic women treated with teriparatide (TPTD) for up to 18 months, in a naturalistic setting. Methods. 301 patients provided baseline information on demographic characteristics, fracture history, osteoporosis-related medication and risk factors. During treatment, QoL and BP severity were evaluated. Results. Mean (SD) age was 69.5 (±8.5) years. Fracture history was reported by 92.5% of patients. Incidence of fractures (per 10,000 patients/years) ranged from 402 during 0–6 months of treatment, to 346 during 12–18 months. All 5 dimensions of QoL showed improvement. At baseline and 18 months, BP was reported by 93.2% and 64.2% of patients, respectively. BP and limitation of activities were quantified as moderate or severe by 89.9% and 62.3% of patients at baseline versus 32.4% and 14.8% at 18 months. Patients on treatment at 6, 12, 17, and 18 months were 92.6%, 88.3%, 79.6%, and 36.5%, respectively. Conclusions. In the Greek EFOS study cohort, patients prescribed TPTD were severely osteoporotic, with considerable health-related problems. Significant improvements in QoL and BP together with low fracture rates and high compliance have been recorded during treatment.http://dx.doi.org/10.4061/2011/510398 |
| spellingShingle | K. Aloumanis D. Karras V. Drossinos E. Korelis A. Polydorakis Fracture Incidence, Quality of Life, and Back Pain during 18-Months Treatment with Teriparatide in Greek Postmenopausal Women with Osteoporosis: Results from the European Forsteo Observational Study Journal of Osteoporosis |
| title | Fracture Incidence, Quality of Life, and Back Pain during 18-Months Treatment with Teriparatide in Greek Postmenopausal Women with Osteoporosis: Results from the European Forsteo Observational Study |
| title_full | Fracture Incidence, Quality of Life, and Back Pain during 18-Months Treatment with Teriparatide in Greek Postmenopausal Women with Osteoporosis: Results from the European Forsteo Observational Study |
| title_fullStr | Fracture Incidence, Quality of Life, and Back Pain during 18-Months Treatment with Teriparatide in Greek Postmenopausal Women with Osteoporosis: Results from the European Forsteo Observational Study |
| title_full_unstemmed | Fracture Incidence, Quality of Life, and Back Pain during 18-Months Treatment with Teriparatide in Greek Postmenopausal Women with Osteoporosis: Results from the European Forsteo Observational Study |
| title_short | Fracture Incidence, Quality of Life, and Back Pain during 18-Months Treatment with Teriparatide in Greek Postmenopausal Women with Osteoporosis: Results from the European Forsteo Observational Study |
| title_sort | fracture incidence quality of life and back pain during 18 months treatment with teriparatide in greek postmenopausal women with osteoporosis results from the european forsteo observational study |
| url | http://dx.doi.org/10.4061/2011/510398 |
| work_keys_str_mv | AT kaloumanis fractureincidencequalityoflifeandbackpainduring18monthstreatmentwithteriparatideingreekpostmenopausalwomenwithosteoporosisresultsfromtheeuropeanforsteoobservationalstudy AT dkarras fractureincidencequalityoflifeandbackpainduring18monthstreatmentwithteriparatideingreekpostmenopausalwomenwithosteoporosisresultsfromtheeuropeanforsteoobservationalstudy AT vdrossinos fractureincidencequalityoflifeandbackpainduring18monthstreatmentwithteriparatideingreekpostmenopausalwomenwithosteoporosisresultsfromtheeuropeanforsteoobservationalstudy AT ekorelis fractureincidencequalityoflifeandbackpainduring18monthstreatmentwithteriparatideingreekpostmenopausalwomenwithosteoporosisresultsfromtheeuropeanforsteoobservationalstudy AT apolydorakis fractureincidencequalityoflifeandbackpainduring18monthstreatmentwithteriparatideingreekpostmenopausalwomenwithosteoporosisresultsfromtheeuropeanforsteoobservationalstudy |